Nuveen Asset Management, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$59,013,118
+20.1%
1,544,846
+13.4%
0.02%
+23.5%
Q2 2023$49,152,769
+104152.1%
1,362,705
+10.4%
0.02%
-5.6%
Q1 2023$47,148
-16.8%
1,234,558
+24.0%
0.02%
-18.2%
Q4 2022$56,645
-99.9%
995,536
-3.9%
0.02%
+29.4%
Q3 2022$40,945,000
-8.3%
1,035,523
+2.0%
0.02%0.0%
Q2 2022$44,650,000
+24.9%
1,014,796
+5.6%
0.02%
+41.7%
Q1 2022$35,761,000
-8.3%
961,334
-0.9%
0.01%0.0%
Q4 2021$39,016,000
-5.2%
970,318
-4.1%
0.01%
-7.7%
Q3 2021$41,161,000
-1.3%
1,011,808
+10.2%
0.01%
+8.3%
Q2 2021$41,703,000
+12.2%
918,352
+3.0%
0.01%0.0%
Q1 2021$37,166,000
-14.3%
891,506
-12.2%
0.01%
-20.0%
Q4 2020$43,381,000
+58.8%
1,015,711
-2.3%
0.02%
+36.4%
Q3 2020$27,321,000
-0.8%
1,039,620
+1.2%
0.01%0.0%
Q2 2020$27,549,000
+40.1%
1,027,577
-6.0%
0.01%
+10.0%
Q1 2020$19,661,000
-22.3%
1,092,902
-23.4%
0.01%0.0%
Q4 2019$25,306,000
+28.9%
1,427,325
+12.8%
0.01%
+25.0%
Q3 2019$19,625,000
-23.1%
1,265,341
-14.9%
0.01%
-20.0%
Q2 2019$25,530,000
+6514.0%
1,486,081
+6394.3%
0.01%
+400.0%
Q2 2018$386,000
-17.3%
22,883
-4.0%
0.00%
-33.3%
Q1 2018$467,000
-3.3%
23,8460.0%0.00%0.0%
Q4 2017$483,00023,8460.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders